1 Data
1.1 baseline
Patient’s Baseline Characteristics
|
|
level
|
1 ROBOT
|
2 LPS+LESS
|
p
|
test
|
SMD
|
|
n
|
|
478
|
1539
|
|
|
|
|
ECOG (%)
|
0 無症狀
|
248 (51.9)
|
608 (39.5)
|
<0.001
|
|
0.521
|
|
|
1 有症狀,可步行對生活不影響
|
187 (39.1)
|
534 (34.7)
|
|
|
|
|
|
2 躺在床上時間小於50%
|
21 ( 4.4)
|
81 ( 5.3)
|
|
|
|
|
|
3 躺在床上時間大於50%
|
3 ( 0.6)
|
9 ( 0.6)
|
|
|
|
|
|
4 完全臥床
|
0 ( 0.0)
|
4 ( 0.3)
|
|
|
|
|
|
NA
|
19 ( 4.0)
|
303 (19.7)
|
|
|
|
|
性別 (%)
|
1 男
|
202 (42.3)
|
633 (41.1)
|
0.701
|
|
0.023
|
|
|
2 女
|
276 (57.7)
|
906 (58.9)
|
|
|
|
|
BMI (%)
|
Normal
|
227 (47.5)
|
581 (37.8)
|
<0.001
|
|
0.318
|
|
|
Overweight
|
133 (27.8)
|
353 (22.9)
|
|
|
|
|
|
NA
|
118 (24.7)
|
605 (39.3)
|
|
|
|
|
診斷年紀 (mean (SD))
|
|
69.29 (10.24)
|
68.74 (10.48)
|
0.317
|
|
0.053
|
|
Cell_Type (%)
|
1 urothelial
|
413 (86.4)
|
1385 (90.0)
|
0.076
|
|
0.114
|
|
|
5 UC with variants (Squamous cell, glandular, sarcomatous, micro
papillary, neuroendocrine, lymphoepithelial)
|
61 (12.8)
|
147 ( 9.6)
|
|
|
|
|
|
6 others
|
4 ( 0.8)
|
7 ( 0.5)
|
|
|
|
|
左右側 (%)
|
1 左
|
248 (51.9)
|
800 (52.0)
|
0.988
|
|
0.008
|
|
|
2 右
|
223 (46.7)
|
715 (46.5)
|
|
|
|
|
|
3 雙側
|
7 ( 1.5)
|
24 ( 1.6)
|
|
|
|
|
腫瘤位置 (%)
|
0 non-visible
|
1 ( 0.2)
|
1 ( 0.1)
|
NaN
|
|
0.101
|
|
|
1 腎盂
|
186 (38.9)
|
652 (42.4)
|
|
|
|
|
|
2 輸尿管
|
175 (36.6)
|
499 (32.4)
|
|
|
|
|
|
3 膀胱袖口
|
1 ( 0.2)
|
2 ( 0.1)
|
|
|
|
|
|
4 多個位置
|
115 (24.1)
|
385 (25.0)
|
|
|
|
|
|
5 無法識別
|
0 ( 0.0)
|
0 ( 0.0)
|
|
|
|
|
多發性 (%)
|
0 Not available
|
18 ( 3.8)
|
90 ( 5.8)
|
0.209
|
|
0.098
|
|
|
1 No
|
295 (61.7)
|
933 (60.6)
|
|
|
|
|
|
2 Yes
|
165 (34.5)
|
516 (33.5)
|
|
|
|
|
腫瘤大小 (%)
|
0 Not available
|
7 ( 1.5)
|
55 ( 3.6)
|
0.057
|
|
0.138
|
|
|
1 <2cm
|
152 (31.8)
|
460 (29.9)
|
|
|
|
|
|
2 >=2cm
|
319 (66.7)
|
1024 (66.5)
|
|
|
|
|
病理分期 (%)
|
1 stage 0a/0is
|
73 (15.3)
|
241 (15.7)
|
0.015
|
|
0.188
|
|
|
2 stage I
|
118 (24.7)
|
434 (28.2)
|
|
|
|
|
|
3 stage II
|
79 (16.5)
|
296 (19.2)
|
|
|
|
|
|
4 stage III
|
144 (30.1)
|
442 (28.7)
|
|
|
|
|
|
5 stage IV
|
52 (10.9)
|
106 ( 6.9)
|
|
|
|
|
|
NA
|
12 ( 2.5)
|
20 ( 1.3)
|
|
|
|
|
完整檢體腫瘤惡性度 (%)
|
1 papillary urothelial neoplasm of low malignant potential
|
1 ( 0.2)
|
1 ( 0.1)
|
0.190
|
|
0.123
|
|
|
2 low grade
|
47 ( 9.8)
|
139 ( 9.0)
|
|
|
|
|
|
3 high grade
|
418 (87.4)
|
1369 (89.0)
|
|
|
|
|
|
4 Gx
|
2 ( 0.4)
|
15 ( 1.0)
|
|
|
|
|
|
NA
|
10 ( 2.1)
|
15 ( 1.0)
|
|
|
|
|
合併膀胱腫瘤 (%)
|
0 No
|
355 (74.3)
|
1072 (69.7)
|
0.092
|
|
0.160
|
|
|
1 Previous Hx of bladder UC
|
33 ( 6.9)
|
114 ( 7.4)
|
|
|
|
|
|
2 Concurrent Bladder UC
|
70 (14.6)
|
261 (17.0)
|
|
|
|
|
|
3 Not available
|
14 ( 2.9)
|
41 ( 2.7)
|
|
|
|
|
|
NA
|
6 ( 1.3)
|
51 ( 3.3)
|
|
|
|
|
合併CIS (%)
|
0 No
|
323 (67.6)
|
1057 (68.7)
|
0.096
|
|
0.121
|
|
|
1 Yes
|
148 (31.0)
|
434 (28.2)
|
|
|
|
|
|
NA
|
7 ( 1.5)
|
48 ( 3.1)
|
|
|
|
|
Lymphovascular_invasion (%)
|
0 No
|
365 (76.4)
|
1254 (81.5)
|
<0.001
|
|
0.195
|
|
|
1 Yes
|
92 (19.2)
|
264 (17.2)
|
|
|
|
|
|
NA
|
21 ( 4.4)
|
21 ( 1.4)
|
|
|
|
|
surgical_margin (%)
|
0 free
|
448 (93.7)
|
1469 (95.5)
|
0.085
|
|
0.110
|
|
|
1 positive
|
26 ( 5.4)
|
51 ( 3.3)
|
|
|
|
|
|
NA
|
4 ( 0.8)
|
19 ( 1.2)
|
|
|
|
|
術前水腎 (%)
|
1 No
|
207 (43.3)
|
715 (46.5)
|
0.151
|
|
0.104
|
|
|
2 Yes
|
257 (53.8)
|
759 (49.3)
|
|
|
|
|
|
NA
|
14 ( 2.9)
|
65 ( 4.2)
|
|
|
|
|
Tumor_Necrosis (%)
|
0 No
|
411 (86.0)
|
1131 (73.5)
|
<0.001
|
|
0.433
|
|
|
1 Yes
|
57 (11.9)
|
208 (13.5)
|
|
|
|
|
|
NA
|
10 ( 2.1)
|
200 (13.0)
|
|
|
|
|
有無針對UTUC化療 (%)
|
0 No
|
321 (67.2)
|
1071 (69.6)
|
0.020
|
|
0.154
|
|
|
1 Yes
|
147 (30.8)
|
402 (26.1)
|
|
|
|
|
|
2 Not available
|
10 ( 2.1)
|
66 ( 4.3)
|
|
|
|
|
針對UTUC化療型態 (%)
|
0 No & Unknown
|
331 (69.2)
|
1135 (73.7)
|
0.011
|
|
0.172
|
|
|
1 neo-adjuvant
|
19 ( 4.0)
|
42 ( 2.7)
|
|
|
|
|
|
2 adjuvant
|
92 (19.2)
|
296 (19.2)
|
|
|
|
|
|
3 salvage (curative intent)
|
13 ( 2.7)
|
15 ( 1.0)
|
|
|
|
|
|
4 palliative (S/S relieve)
|
23 ( 4.8)
|
51 ( 3.3)
|
|
|
|
|
化療處方 (%)
|
0 No & Unknown
|
336 (70.3)
|
1146 (74.5)
|
0.089
|
|
0.148
|
|
|
1 Gemcitabine & cisplatin
|
39 ( 8.2)
|
124 ( 8.1)
|
|
|
|
|
|
2 MVAC
|
10 ( 2.1)
|
11 ( 0.7)
|
|
|
|
|
|
3 Taxans-based
|
0 ( 0.0)
|
1 ( 0.1)
|
|
|
|
|
|
4 Carboplatin-based
|
49 (10.3)
|
141 ( 9.2)
|
|
|
|
|
|
5 others
|
44 ( 9.2)
|
116 ( 7.5)
|
|
|
|
|
Bladder_cuff_resection (%)
|
0 Not perform BCR
|
11 ( 2.3)
|
46 ( 3.0)
|
<0.001
|
|
2.195
|
|
|
1 Open incision
|
92 (19.2)
|
1026 (66.7)
|
|
|
|
|
|
2 Transurethral incision
|
9 ( 1.9)
|
54 ( 3.5)
|
|
|
|
|
|
4 Laparoscopy
|
6 ( 1.3)
|
303 (19.7)
|
|
|
|
|
|
5 Robot assisted
|
321 (67.2)
|
5 ( 0.3)
|
|
|
|
|
|
NA
|
39 ( 8.2)
|
105 ( 6.8)
|
|
|
|
|
simultaneously_ipsilateral_adrenalectomy (%)
|
0 No
|
407 (85.1)
|
1203 (78.2)
|
0.002
|
|
0.196
|
|
|
1 Yes
|
26 ( 5.4)
|
95 ( 6.2)
|
|
|
|
|
|
NA
|
45 ( 9.4)
|
241 (15.7)
|
|
|
|
|
Post_operation_intravesical_CT_instillation (%)
|
1 No
|
356 (74.5)
|
1366 (88.8)
|
<0.001
|
|
0.478
|
|
|
2 術中膀胱灌藥
|
41 ( 8.6)
|
6 ( 0.4)
|
|
|
|
|
|
3 術後膀胱灌藥
|
38 ( 7.9)
|
50 ( 3.2)
|
|
|
|
|
|
NA
|
43 ( 9.0)
|
117 ( 7.6)
|
|
|
|
|
Clavien_Dindo_classification (%)
|
0 No Complication
|
284 (59.4)
|
900 (58.5)
|
0.008
|
|
0.249
|
|
|
1 Grade I
|
78 (16.3)
|
175 (11.4)
|
|
|
|
|
|
2 Grade II
|
76 (15.9)
|
239 (15.5)
|
|
|
|
|
|
3 Grade IIIa
|
4 ( 0.8)
|
14 ( 0.9)
|
|
|
|
|
|
4 Grade IIIb
|
4 ( 0.8)
|
21 ( 1.4)
|
|
|
|
|
|
5 Grade IVa
|
3 ( 0.6)
|
15 ( 1.0)
|
|
|
|
|
|
6 Grade IVb
|
0 ( 0.0)
|
1 ( 0.1)
|
|
|
|
|
|
7 Grade V
|
3 ( 0.6)
|
6 ( 0.4)
|
|
|
|
|
|
NA
|
26 ( 5.4)
|
168 (10.9)
|
|
|
|
|
Disease_free (%)
|
0 No
|
107 (22.4)
|
257 (16.7)
|
<0.001
|
|
0.241
|
|
|
1 Yes
|
317 (66.3)
|
1084 (70.4)
|
|
|
|
|
|
3 Segmental resection 後復發或轉移
|
11 ( 2.3)
|
6 ( 0.4)
|
|
|
|
|
|
4 Unknown
|
43 ( 9.0)
|
192 (12.5)
|
|
|
|
|
Mortality (%)
|
0 No
|
312 (65.3)
|
835 (54.3)
|
<0.001
|
|
0.342
|
|
|
1 UTUC related
|
66 (13.8)
|
175 (11.4)
|
|
|
|
|
|
2 Non-UTUC related
|
44 ( 9.2)
|
231 (15.0)
|
|
|
|
|
|
3 死因不明
|
27 ( 5.6)
|
203 (13.2)
|
|
|
|
|
|
4 Surgery related
|
2 ( 0.4)
|
9 ( 0.6)
|
|
|
|
|
|
5 無法判斷生死
|
27 ( 5.6)
|
86 ( 5.6)
|
|
|
|
|
術後住院天數_day (mean (SD))
|
|
7.60 (4.16)
|
8.44 (5.68)
|
0.004
|
|
0.168
|
|
手術到死亡間隔時間_月 (mean (SD))
|
|
24.10 (17.50)
|
38.77 (32.74)
|
<0.001
|
|
0.559
|
|
Longest_follow_up_month_for_BDFS_DFS (mean (SD))
|
|
31.38 (22.82)
|
39.23 (31.65)
|
<0.001
|
|
0.285
|
|
Followup (mean (SD))
|
|
48.06 (95.91)
|
52.79 (39.89)
|
0.124
|
|
0.064
|
2 Impute Missing Value
We utilize MICE to impute the missing value, since too
much missing value.
2.1 MICE
MICE stands for Multivariate Imputation by Chained Equations. It is a
statistical method used to handle missing data in a dataset. The process
uses multiple imputation techniques to fill in the missing data and then
combines the results from multiple imputations to produce a final
imputed dataset.
\(\text{Table}\:\text{1.}\) Robot vs
LPS+LESS after imputing the missing value.
|
|
Robot
|
LPS+LESS
|
total
|
|
N
|
477
|
1539
|
2016
|
After MICE
|
|
level
|
1 Robot
|
2 LPS+LESS
|
p
|
test
|
SMD
|
|
n
|
|
477
|
1539
|
|
|
|
|
ECOG (%)
|
0 無症狀
|
255 (53.5)
|
736 (47.8)
|
0.005
|
|
0.233
|
|
|
1 有症狀,可步行對生活不影響
|
193 (40.5)
|
640 (41.6)
|
|
|
|
|
|
2 躺在床上時間小於50%
|
23 ( 4.8)
|
116 ( 7.5)
|
|
|
|
|
|
3 躺在床上時間大於50%
|
6 ( 1.3)
|
20 ( 1.3)
|
|
|
|
|
|
4 完全臥床
|
0 ( 0.0)
|
27 ( 1.8)
|
|
|
|
|
性別 (%)
|
1 男
|
202 (42.3)
|
633 (41.1)
|
0.676
|
|
0.025
|
|
|
2 女
|
275 (57.7)
|
906 (58.9)
|
|
|
|
|
BMI (%)
|
1 Normal
|
299 (62.7)
|
956 (62.1)
|
0.866
|
|
0.012
|
|
|
2 Overweight
|
178 (37.3)
|
583 (37.9)
|
|
|
|
|
Cell_Type (%)
|
1 urothelial
|
412 (86.4)
|
1385 (90.0)
|
0.074
|
|
0.115
|
|
|
5 UC with variants
|
61 (12.8)
|
147 ( 9.6)
|
|
|
|
|
|
6 others
|
4 ( 0.8)
|
7 ( 0.5)
|
|
|
|
|
左右側 (%)
|
1 左
|
248 (52.0)
|
800 (52.0)
|
0.990
|
|
0.008
|
|
|
2 右
|
222 (46.5)
|
715 (46.5)
|
|
|
|
|
|
3 雙側
|
7 ( 1.5)
|
24 ( 1.6)
|
|
|
|
|
腫瘤位置 (%)
|
0 non-visible
|
1 ( 0.2)
|
1 ( 0.1)
|
0.395
|
|
0.102
|
|
|
1 腎盂
|
186 (39.0)
|
652 (42.4)
|
|
|
|
|
|
2 輸尿管
|
175 (36.7)
|
499 (32.4)
|
|
|
|
|
|
3 膀胱袖口
|
1 ( 0.2)
|
2 ( 0.1)
|
|
|
|
|
|
4 多個位置
|
114 (23.9)
|
385 (25.0)
|
|
|
|
|
多發性 (%)
|
0 Not available
|
18 ( 3.8)
|
90 ( 5.8)
|
0.213
|
|
0.097
|
|
|
1 No
|
295 (61.8)
|
933 (60.6)
|
|
|
|
|
|
2 Yes
|
164 (34.4)
|
516 (33.5)
|
|
|
|
|
腫瘤大小 (%)
|
0 Not available
|
7 ( 1.5)
|
55 ( 3.6)
|
0.057
|
|
0.138
|
|
|
1 <2cm
|
152 (31.9)
|
460 (29.9)
|
|
|
|
|
|
2 >=2cm
|
318 (66.7)
|
1024 (66.5)
|
|
|
|
|
病理分期 (%)
|
1 stage 0a/0is
|
74 (15.5)
|
247 (16.0)
|
0.026
|
|
0.167
|
|
|
2 stage I
|
123 (25.8)
|
441 (28.7)
|
|
|
|
|
|
3 stage II
|
81 (17.0)
|
301 (19.6)
|
|
|
|
|
|
4 stage III
|
146 (30.6)
|
444 (28.8)
|
|
|
|
|
|
5 stage IV
|
53 (11.1)
|
106 ( 6.9)
|
|
|
|
|
完整檢體腫瘤惡性度 (%)
|
1 papillary urothelial neoplasm of low malignant potential
|
1 ( 0.2)
|
1 ( 0.1)
|
0.780
|
|
0.049
|
|
|
2 low grade
|
47 ( 9.9)
|
140 ( 9.1)
|
|
|
|
|
|
3 high grade
|
425 (89.1)
|
1383 (89.9)
|
|
|
|
|
|
4 Gx
|
4 ( 0.8)
|
15 ( 1.0)
|
|
|
|
|
合併膀胱腫瘤 (%)
|
0 No
|
359 (75.3)
|
1115 (72.4)
|
0.600
|
|
0.073
|
|
|
1 Previous Hx of bladder UC
|
33 ( 6.9)
|
117 ( 7.6)
|
|
|
|
|
|
2 Concurrent Bladder UC
|
71 (14.9)
|
265 (17.2)
|
|
|
|
|
|
3 Not available
|
14 ( 2.9)
|
42 ( 2.7)
|
|
|
|
|
合併CIS (%)
|
0 No
|
329 (69.0)
|
1091 (70.9)
|
0.457
|
|
0.042
|
|
|
1 Yes
|
148 (31.0)
|
448 (29.1)
|
|
|
|
|
Lymphovascular_invasion (%)
|
0 No
|
384 (80.5)
|
1269 (82.5)
|
0.367
|
|
0.050
|
|
|
1 Yes
|
93 (19.5)
|
270 (17.5)
|
|
|
|
|
surgical_margin (%)
|
0 Free
|
450 (94.3)
|
1488 (96.7)
|
0.029
|
|
0.114
|
|
|
1 Positive
|
27 ( 5.7)
|
51 ( 3.3)
|
|
|
|
|
術前水腎 (%)
|
0 No
|
214 (44.9)
|
757 (49.2)
|
0.110
|
|
0.087
|
|
|
1 Yes
|
263 (55.1)
|
782 (50.8)
|
|
|
|
|
Tumor_Necrosis (%)
|
0 No
|
420 (88.1)
|
1267 (82.3)
|
0.004
|
|
0.162
|
|
|
1 Yes
|
57 (11.9)
|
272 (17.7)
|
|
|
|
|
有無針對UTUC化療 (%)
|
0 No
|
320 (67.1)
|
1071 (69.6)
|
0.019
|
|
0.154
|
|
|
1 Yes
|
147 (30.8)
|
402 (26.1)
|
|
|
|
|
|
2 Not available
|
10 ( 2.1)
|
66 ( 4.3)
|
|
|
|
|
針對UTUC化療型態 (%)
|
0 No & Unknown
|
330 (69.2)
|
1135 (73.7)
|
0.010
|
|
0.173
|
|
|
1 neo-adjuvant
|
19 ( 4.0)
|
42 ( 2.7)
|
|
|
|
|
|
2 adjuvant
|
92 (19.3)
|
296 (19.2)
|
|
|
|
|
|
3 salvage (curative intent)
|
13 ( 2.7)
|
15 ( 1.0)
|
|
|
|
|
|
4 palliative (S/S relieve)
|
23 ( 4.8)
|
51 ( 3.3)
|
|
|
|
|
化療處方 (%)
|
0 No & Unknown
|
335 (70.2)
|
1146 (74.5)
|
0.049
|
|
0.148
|
|
|
1 Gemcitabine & cisplatin
|
39 ( 8.2)
|
124 ( 8.1)
|
|
|
|
|
|
2 MVAC
|
10 ( 2.1)
|
11 ( 0.7)
|
|
|
|
|
|
3 Taxans-based
|
0 ( 0.0)
|
1 ( 0.1)
|
|
|
|
|
|
5 others
|
93 (19.5)
|
257 (16.7)
|
|
|
|
|
Bladder_cuff_resection (%)
|
0 Not perform BCR
|
13 ( 2.7)
|
55 ( 3.6)
|
<0.001
|
|
2.296
|
|
|
1 Open incision
|
103 (21.6)
|
1084 (70.4)
|
|
|
|
|
|
2 Transurethral incision
|
10 ( 2.1)
|
62 ( 4.0)
|
|
|
|
|
|
4 Laparoscopy
|
9 ( 1.9)
|
332 (21.6)
|
|
|
|
|
|
5 Robot assisted
|
342 (71.7)
|
6 ( 0.4)
|
|
|
|
|
simultaneously_ipsilateral_adrenalectomy (%)
|
0 No
|
443 (92.9)
|
1409 (91.6)
|
0.409
|
|
0.049
|
|
|
1 Yes
|
34 ( 7.1)
|
130 ( 8.4)
|
|
|
|
|
Post_operation_intravesical_CT_instillation (%)
|
0 No
|
392 (82.2)
|
1463 (95.1)
|
<0.001
|
|
0.452
|
|
|
1 術中膀胱灌藥
|
43 ( 9.0)
|
10 ( 0.6)
|
|
|
|
|
|
2 術後膀胱灌藥
|
42 ( 8.8)
|
66 ( 4.3)
|
|
|
|
|
診斷年紀 (mean (SD))
|
|
69.28 (10.25)
|
68.75 (10.48)
|
0.330
|
|
0.051
|
|
Clavien_Dindo_classification (%)
|
0 No Complication
|
298 (62.5)
|
990 (64.3)
|
0.430
|
|
0.140
|
|
|
1 Grade I
|
80 (16.8)
|
201 (13.1)
|
|
|
|
|
|
2 Grade II
|
81 (17.0)
|
267 (17.3)
|
|
|
|
|
|
3 Grade IIIa
|
4 ( 0.8)
|
19 ( 1.2)
|
|
|
|
|
|
4 Grade IIIb
|
5 ( 1.0)
|
26 ( 1.7)
|
|
|
|
|
|
5 Grade IVa
|
3 ( 0.6)
|
17 ( 1.1)
|
|
|
|
|
|
6 Grade IVb
|
1 ( 0.2)
|
7 ( 0.5)
|
|
|
|
|
|
7 Grade V
|
5 ( 1.0)
|
12 ( 0.8)
|
|
|
|
|
Disease_free (%)
|
0 No
|
107 (22.4)
|
257 (16.7)
|
0.006
|
|
0.145
|
|
|
1 Yes
|
370 (77.6)
|
1282 (83.3)
|
|
|
|
|
Mortality (%)
|
0 No
|
311 (65.2)
|
835 (54.3)
|
<0.001
|
|
0.225
|
|
|
1 Yes
|
166 (34.8)
|
704 (45.7)
|
|
|
|
|
術後住院天數_day (mean (SD))
|
|
7.58 (4.12)
|
8.52 (5.69)
|
0.001
|
|
0.189
|
|
Followup (mean (SD))
|
|
43.72 (30.89)
|
52.39 (39.77)
|
<0.001
|
|
0.243
|
|
Followup_DF (mean (SD))
|
|
31.36 (22.77)
|
39.07 (31.54)
|
<0.001
|
|
0.280
|
3 Overlap weighting

After
after overlap weighting
|
|
level
|
1 Robot
|
2 LPS+LESS
|
p
|
test
|
SMD
|
|
n
|
|
478.0
|
1539.0
|
|
|
|
|
Clavien_Dindo_classification (%)
|
0 No Complication
|
267.9 (56.0)
|
964.0 (62.6)
|
0.419
|
|
0.217
|
|
|
1 Grade I
|
78.0 (16.3)
|
207.0 (13.5)
|
|
|
|
|
|
2 Grade II
|
107.6 (22.5)
|
298.2 (19.4)
|
|
|
|
|
|
3 Grade IIIa
|
9.0 ( 1.9)
|
17.0 ( 1.1)
|
|
|
|
|
|
4 Grade IIIb
|
11.4 ( 2.4)
|
25.9 ( 1.7)
|
|
|
|
|
|
5 Grade IVa
|
0.1 ( 0.0)
|
14.2 ( 0.9)
|
|
|
|
|
|
6 Grade IVb
|
3.6 ( 0.7)
|
6.3 ( 0.4)
|
|
|
|
|
|
7 Grade V
|
0.5 ( 0.1)
|
6.3 ( 0.4)
|
|
|
|
|
Disease_free (%)
|
0 No
|
91.6 (19.2)
|
288.1 (18.7)
|
<0.001
|
|
0.308
|
|
|
1 Yes
|
325.0 (68.0)
|
1077.5 (70.0)
|
|
|
|
|
|
3 Segmental resection 後復發或轉移
|
23.8 ( 5.0)
|
4.9 ( 0.3)
|
|
|
|
|
|
4 Unknown
|
37.7 ( 7.9)
|
168.5 (11.0)
|
|
|
|
|
Mortality (%)
|
0 No
|
304.8 (63.8)
|
870.9 (56.6)
|
0.115
|
|
0.147
|
|
|
1 Yes
|
173.2 (36.2)
|
668.1 (43.4)
|
|
|
|
|
術後住院天數_day (mean (SD))
|
|
7.23 (3.36)
|
8.17 (5.36)
|
0.005
|
|
0.210
|
Before
before overlap weighting
|
|
level
|
1 Robot
|
2 LPS+LESS
|
p
|
test
|
SMD
|
|
n
|
|
477
|
1539
|
|
|
|
|
Clavien_Dindo_classification (%)
|
0 No Complication
|
298 (62.5)
|
990 (64.3)
|
0.430
|
|
0.140
|
|
|
1 Grade I
|
80 (16.8)
|
201 (13.1)
|
|
|
|
|
|
2 Grade II
|
81 (17.0)
|
267 (17.3)
|
|
|
|
|
|
3 Grade IIIa
|
4 ( 0.8)
|
19 ( 1.2)
|
|
|
|
|
|
4 Grade IIIb
|
5 ( 1.0)
|
26 ( 1.7)
|
|
|
|
|
|
5 Grade IVa
|
3 ( 0.6)
|
17 ( 1.1)
|
|
|
|
|
|
6 Grade IVb
|
1 ( 0.2)
|
7 ( 0.5)
|
|
|
|
|
|
7 Grade V
|
5 ( 1.0)
|
12 ( 0.8)
|
|
|
|
|
Disease_free (%)
|
0 No
|
107 (22.4)
|
257 (16.7)
|
0.006
|
|
0.145
|
|
|
1 Yes
|
370 (77.6)
|
1282 (83.3)
|
|
|
|
|
Mortality (%)
|
0 No
|
311 (65.2)
|
835 (54.3)
|
<0.001
|
|
0.225
|
|
|
1 Yes
|
166 (34.8)
|
704 (45.7)
|
|
|
|
|
術後住院天數_day (mean (SD))
|
|
7.58 (4.12)
|
8.52 (5.69)
|
0.001
|
|
0.189
|
4 Modeling
p-value

5 Survival Curve
OS

DFS
